Authors
Yangdong Ding, Linmin Pan, Jie Chen, Yanxu Jiang, Linfeng Liu, Jin Zhang, Mingtong Chen, Junjie Zhu, Yue Gao, Wenwu Zhang, Junjie Liang, Puhong Zhang, Shengwei Jin
Published in
Cell reports. Volume 45. Issue 11. Pages 118284. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
Vascular endothelial growth factor receptor 3 (VEGFR3) is a key regulator of lymphangiogenesis, but its role in platelets remains undefined. Here, we identify VEGFR3 as an intrinsic inhibitory regulator of platelet function. Using PF4-Cre-mediated conditional deletion, pharmacological inhibition, and biochemical analyses, we show that VEGFR3 deficiency enhances platelet activation, aggregation, secretion, cytoskeletal remodeling, thrombosis, and myocardial injury. Mechanistically, VEGFR3 interacts with the Rho GTPase regulator p190A to limit RhoA activation and Ezrin/Radixin/Moesin phosphorylation, thereby restraining platelet activation. In patients with myocardial infarction, reduced platelet VEGFR3 expression is associated with increased platelet reactivity and greater coronary lesion severity. These findings uncover a previously unrecognized VEGFR3/p190A/RhoA signaling axis that restrains platelet activation and thrombosis and highlight its potential therapeutic relevance in thrombotic disorders.
PMID:
43013393
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0